Gene

KIT

KIT proto-oncogene, receptor tyrosine kinase

Explore in graph →CI-GENE-00006972HGNC:6342 ENSG00000157404 NCBI 3815 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (312)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 51–100 of 312 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KIT D816V7
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	4

Cohorts

Alteration frequency by cohort (130)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved130 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Gastrointestinal Stromal Tumor (MSK 2025) gist_msk_2025	Gastrointestinal Stromal Tumor	Ssm	174	183	95.1%

Literature

Linked publications (44)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 44 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
· J Clin Oncol · 2003 · PMID 14645423 · validated civic_curation pubmed
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
· Eur J Cancer · 2006 · PMID 16624552 · validated civic_curation pubmed
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
· J Clin Oncol · 2006 · PMID 16954519 · validated civic_curation pubmed
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.
· Blood · 2006 · PMID 16384925 · validated civic_curation pubmed

KIT D816Y2
Ponatinib + Regorafenib + SunitinibSubstitutes	Gastrointestinal Stromal Tumor	Predictive	D	Supports Resistance	2	submitted	EID4156 In an in vitro study, a Ba/F3 cell line expressing KIT 557-558del primary mutation (known to confer sensitivity to regorafenib) was incubated in various concentrations of ponatinib, sunitinib, or rego… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
Sunitinib	Gastrointestinal Stromal Tumor	Predictive	D	Supports Resistance	—	submitted	EID4155 In an in vitro study, a 32D cell line expressing KIT D816Y mutation (overexpression) demonstrated reduced sensitivity to sunitinib treatment (IC50: 73.1nM) compared to 32D cells expressing wild-type K… (full text at CIViC) PMID 24205792 · Zhao et al., 2014 · Open in CIViC	civic

KIT D816Y2

Ponatinib + Regorafenib + SunitinibSubstitutes

Gastrointestinal Stromal Tumor

Predictive

Supports Resistance

submitted

EID4156

In an in vitro study, a Ba/F3 cell line expressing KIT 557-558del primary mutation (known to confer sensitivity to regorafenib) was incubated in various concentrations of ponatinib, sunitinib, or rego… (full text at CIViC)

PMID 25239608 · Garner et al., 2014 · Open in CIViC

KIT D820Y4
(prognostic)	Melanoma	Prognostic	C	Supports N/A	2	submitted	EID2887 261 Australian patients with melanoma were screened for mutations in KIT exons 11,13 and 17. 5 KIT mutations were found, including in 2 of the 4 total acral melanomas assessed. 1 subject with acral me… (full text at CIViC) PMID 20088873 · Handolias et al., 2010 · Open in CIViC	civic
Imatinib	Melanoma	Predictive	C	Supports Resistance	3	accepted	EID2886 FFPE tumor specimens from 295 melanoma patients were screened for KIT amplification and mutation. Of these, 51 patients had variants in KIT and 28 of these were treated with imatinib mesylate at 400 m… (full text at CIViC) PMID 21642685 · Carvajal et al., 2011 · Open in CIViC	civic
Regorafenib Anhydrous	Gastrointestinal Stromal Tumor	Predictive	C	Supports Sensitivity Response	2	accepted	EID4589 This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib a… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC	civic
Sunitinib	Melanoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID2888 28 acral or mucosal melanomas were examined for KIT expression and mutations (exons 11, 13, 17, and 18). Two of 19 melanomas examined harbored KIT mutations, with one subject harboring a D820Y mutatio… (full text at CIViC) PMID 19035443 · Ashida et al., 2009 · Open in CIViC	civic